PET/CT Imaging in Patients with Vulvar and Vaginal Cancer
PDF
Cite
Share
Request
Review
P: 182-189
November 2022

PET/CT Imaging in Patients with Vulvar and Vaginal Cancer

Nucl Med Semin 2022;8(3):182-189
1. İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Vulva and vagina cancers are seen at a very low rate among gynecological malignancies. They mostly appear in the postmenopausal period and in advanced age. Although many subtypes have been associated with HPV, there is no standard screening test and patients are usually diagnosed when become symptomatic. Staging is important for the treatment plan. Surgery is the first choice in the early stage, but combinations of chemotherapy and/or radiotherapy are used in locally advanced and metastatic diseases. F-18 fluorodeoxyglucose positron emission tomography/computerized tomography (PET/CT) not only detects the primary tumor, but also it is quite successful in showing lymph nodes and distant metastasis compared to other imaging methods. PET positivity can completely change the treatment decision be guided to primary chemoradiotherapy by avoiding surgery if positive nodes are detected due to its high specificity. However, false positive findings should not be ignored. Also, there are relatively rare studies in two groups of cancer, it is seen that more studies are needed in especially vaginal cancers. In this review, the contributions of PET/CT in the imaging of vulvar and vaginal cancers will be discussed.

References

1
Creasman WT. Vaginal cancers. Curr Opin Obstet Gynecol 2005;17:71-76.
2
Robertson NL, Hricak H, Sonoda Y, et al. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. Gynecol Oncol 2016;140:420-424.
3
Lin G, Chen CY, Liu FY, et al. Computed tomography, magnetic resonance imaging and FDG positron emission tomography in the management of vulvar malignancies. Eur Radiol 2015;25:1267-1278.
4
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.
5
Alkatout I, Schubert M, Garbrecht N, et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health 2015;7:305-313.
6
Chow L, Tsui BQ, Bahrami S, et al. Gynecologic tumor board: a radiologist's guide to vulvar and vaginal malignancies. Abdom Radiol (NY) 2021;46:5669-5586.
7
Scurry J. Does lichen sclerosus play a central role in the pathogenesis of human papillomavirus negative vulvar squamous cell carcinoma? The itch-scratch-lichen sclerosus hypothesis. Int J Gynecol Cancer 1999;9:89-97.
8
Stehman FB, Look KY. Carcinoma of the vulva. Obstet Gynecol 2006;107:719-733.
9
Bethesda M. SEER Cancer Statistics Factsheets: Vulvar Cancer. Tamil Nadu: NIH. 2021.
10
Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin"). Int J Radiat Oncol Biol Phys 2006;66:528-536.
11
Kamran MW, O'Toole F, Meghen K, Wahab AN, Saadeh FA, Gleeson N. Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis. Eur J Gynaecol Oncol 2014;35:230-235.
12
Triumbari EKA, de Koster EJ, Rufini V, Fragomeni SM, Garganese G, Collarino A. 18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med 2021;46:125-132.
13
Peiró V, Chiva L, González A, et al. Utilidad de la PET/TC en el manejo del cáncer de vulva. Revista Española de Medicina Nuclear e Imagen Molecular 2014;33:87-92.
14
Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002;85:179-184.
15
Gouveia P, A SP, Violante L, et al. 18F-FDG PET/CT in Patients with Vulvar and Vaginal Cancer: A Preliminary Study of 20 Cases. Acta Med Port 2022;35:170-175.
16
Garganese G, Collarino A, Fragomeni SM, et al. Groin sentinel node biopsy and (18)F-FDG PET/CT-supported preoperative lymph node assessment in cN0 patients with vulvar cancer currently unfit for minimally invasive inguinal surgery: The GroSNaPET study. Eur J Surg Oncol 2017;43:1776-1783.
17
Collarino A, Garganese G, Valdés Olmos RA, et al. Evaluation of Dual-Timepoint (18)F-FDG PET/CT Imaging for Lymph Node Staging in Vulvar Cancer. J Nucl Med 2017;58:1913-1918.
18
Crivellaro C, Guglielmo P, De Ponti E, et al. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective? Medicine (Baltimore) 2017;96:e7943.
19
Dolanbay M, Ozcelik B, Abdulrezzak U, Serin IS, Kutuk MS, Uludag S. F-18 fluoro-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in planning of surgery and sentinel lymph node screening in vulvar cancers. Arch Gynecol Obstet 2016;293:1319-1324.
20
Rufini V, Garganese G, Ieria FP, et al. Diagnostic performance of preoperative [(18)F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study. Eur J Nucl Med Mol Imaging 2021;48:3303-3314.
21
Rao YJ, Hassanzadeh C, Chundury A, et al. Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. Radiother Oncol 2017;122:445-451.
22
Albano D, Bonacina M, Savelli G, et al. Clinical and prognostic (18)F-FDG PET/CT role in recurrent vulvar cancer: a multicentric experience. Jpn J Radiol 2022;40:66-74.
23
Rasmussen CL, Sand FL, Hoffmann Frederiksen M, Kaae Andersen K, Kjaer SK. Does HPV status influence survival after vulvar cancer? Int J Cancer 2018;142:1158-1165.
24
Mokoala KMG, Lawal IO, Lengana T, et al. 18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection. Nuklearmedizin 2020;59:419-427.
25
Sawicki LM, Kirchner J, Grueneisen J, et al. Comparison of (18)F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. Eur J Nucl Med Mol Imaging 2018;45:622-629.
26
Zhang W, Wang Y, Chen W, et al. Verrucous Carcinoma of the Vulva: A Case Report and Literature Review. Am J Case Rep 2019;20:551-556.
27
Sadowski EA, Pirasteh A, McMillan AB, Fowler KJ, Kusmirek JE. PET/MR imaging in gynecologic cancer: tips for differentiating normal gynecologic anatomy and benign pathology versus cancer. Abdom Radiol (NY) 2022;47:3189-31204.
28
Collarino A, Garganese G, Fragomeni SM, et al. Radiomics in vulvar cancer: first clinical experience using 18F-FDG PET/CT images. Journal of nuclear medicine 2019;60:199-206.
29
Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 2008;122:2827-2834.
30
Noor MRM, Tay EH, Low J. Gynaecologic Cancer: Pan Stanford; 2014.
31
Taşkın L. Doğum ve kadın sağlığı hemşireliği: Akademisyen Kitabevi; 2019.
32
Rajaram S, Maheshwari A, Srivastava A. Staging for vaginal cancer. Best Pract Res Clin Obstet Gynaecol 2015;29:822-832.
33
Gauthreaux C, Kuan-Celarier A, Runowicz CD. Vaginal Cancer. The American Cancer Society's Oncology in Practice: Clinical Management 2018:304.
34
Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. International Journal of Gynecology & Obstetrics 2015;131:S84-S87.
35
Sam A, George J, Mathew B. Less Common Gynecologic Malignancies: An Integrative Review. Semin Oncol Nurs 2019;35:175-181.
36
Albuquerque KS, Zoghbi KK, Gomes NBN, et al. Vaginal cancer: Why should we care? Anatomy, staging and in-depth imaging-based review of vaginal malignancies focusing on MRI and PET/CT. Clin Imaging 2022;84:65-78.
37
Yen T-C, Lai C-H, editors. Positron emission tomography in gynecologic cancer. Seminars in nuclear medicine; 2006: Elsevier.
38
Lamoreaux WT, Grigsby PW, Dehdashti F, et al. FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:733-737.
39
Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Benedetti Panici P. Vaginal cancer. Critical Reviews in Oncology/Hematology 2012;81:286-295.
40
Frank SJ, Jhingran A, Levenback C, Eifel PJ. Definitive radiation therapy for squamous cell carcinoma of the vagina. International Journal of Radiation Oncology*Biology*Physics 2005;62:138-147.
41
Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet 2021;155 Suppl 1(Suppl 1):19-27.
42
Rajagopalan MS, Xu KM, Lin JF, Sukumvanich P, Krivak TC, Beriwal S. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. Gynecologic Oncology 2014;135:495-502.
43
Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol 2011;122:190-198.